{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:34:30Z","timestamp":1781375670254,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-80082-1","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:34:50Z","timestamp":1735583690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus"],"prefix":"10.1038","volume":"14","author":[{"given":"Wissal","family":"Liman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Oubahmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouhaila Ait","family":"Lahcen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Hdoufane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Driss","family":"Cherqaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Daoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achraf","family":"El Allali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"80082_CR1","unstructured":"Hepatitis C. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 9 May 2024."},{"issue":"Suppl 1","key":"80082_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/LIV.13027","volume":"36","author":"T Asselah","year":"2016","unstructured":"Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M. & Marcellin, P. Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver Int. 36(Suppl 1), 47\u201357. https:\/\/doi.org\/10.1111\/LIV.13027 (2016).","journal-title":"Liver Int."},{"key":"80082_CR3","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1128\/JVI.68.8.5063-5073.1994","volume":"68","author":"C Lin","year":"1994","unstructured":"Lin, C., Lindenbach, B. D., Pr\u00e1gai, B. M., McCourt, D. W. & Rice, C. M. Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini. J. Virol. 68, 5063\u20135073. https:\/\/doi.org\/10.1128\/JVI.68.8.5063-5073.1994 (1994).","journal-title":"J. Virol."},{"key":"80082_CR4","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1128\/JVI.71.9.6465-6471.1997","volume":"71","author":"C Lin","year":"1997","unstructured":"Lin, C., Wu, J. W., Hsiao, K. & Su, M. S. The hepatitis C virus NS4A protein: Interactions with the NS4B and NS5A proteins. J. Virol. 71, 6465\u20136471. https:\/\/doi.org\/10.1128\/JVI.71.9.6465-6471.1997 (1997).","journal-title":"J. Virol."},{"key":"80082_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/7355_2018_42","volume":"31","author":"KF McDaniel","year":"2019","unstructured":"McDaniel, K. F. et al. The discovery and development of HCV NS3 protease inhibitor paritaprevir, topics in medicinal. Chemistry 31, 389\u2013413. https:\/\/doi.org\/10.1007\/7355_2018_42 (2019).","journal-title":"Chemistry"},{"key":"80082_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2015","unstructured":"Kati, W. et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis c virus polymerase inhibitor. Antimicrob. Agents Chemother. 59, 1505\u20131511. https:\/\/doi.org\/10.1128\/AAC.04619-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"80082_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/J.COPH.2008.09.007","volume":"8","author":"A Kwong","year":"2008","unstructured":"Kwong, A., McNair, L., Jacobson, I. & George, S. Recent progress in the development of selected hepatitis C virus NS3\u00b74A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8, 522\u2013531. https:\/\/doi.org\/10.1016\/J.COPH.2008.09.007 (2008).","journal-title":"Curr. Opin. Pharmacol."},{"key":"80082_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/HEP.27934","volume":"62","author":"E Lontok","year":"2015","unstructured":"Lontok, E. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62, 1623\u20131632. https:\/\/doi.org\/10.1002\/HEP.27934 (2015).","journal-title":"Hepatology"},{"key":"80082_CR9","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","volume":"74","author":"C Sarrazin","year":"2021","unstructured":"Sarrazin, C. Treatment failure with DAA therapy: Importance of resistance. J. Hepatol. 74, 1472\u20131482. https:\/\/doi.org\/10.1016\/j.jhep.2021.03.004 (2021).","journal-title":"J. Hepatol."},{"key":"80082_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1586\/17512433.2016.1129272","volume":"9","author":"SM McConachie","year":"2016","unstructured":"McConachie, S. M., Wilhelm, S. M. & Kale-Pradhan, P. B. New direct-acting antivirals in hepatitis C therapy: A review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev. Clin. Pharmacol. 9, 287\u2013302. https:\/\/doi.org\/10.1586\/17512433.2016.1129272 (2016).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"80082_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/V11010030","volume":"11","author":"N Alazard-Dany","year":"2019","unstructured":"Alazard-Dany, N., Denolly, S., Boson, B. & Cosset, F. L. Overview of HCV life cycle with a special focus on current and possible future antiviral targets. Viruses 11, 30. https:\/\/doi.org\/10.3390\/V11010030 (2019).","journal-title":"Viruses"},{"key":"80082_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/7355_2018_45","volume":"32","author":"DR O\u2019Boyle","year":"2019","unstructured":"O\u2019Boyle, D. R. & Gao, M. NS5A as a target for HCV drug discovery, topics in medicinal. Chemistry 32, 3\u201325. https:\/\/doi.org\/10.1007\/7355_2018_45 (2019).","journal-title":"Chemistry"},{"key":"80082_CR13","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","volume":"85","author":"A Macdonald","year":"2004","unstructured":"Macdonald, A. & Harris, M. Hepatitis C virus NS5A: Tales of a promiscuous protein. J. Gener. Virol. 85, 2485\u20132502. https:\/\/doi.org\/10.1099\/vir.0.80204-0 (2004).","journal-title":"J. Gener. Virol."},{"key":"80082_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/J.GASTRO.2016.04.003","volume":"151","author":"JM Pawlotsky","year":"2016","unstructured":"Pawlotsky, J. M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151, 70\u201386. https:\/\/doi.org\/10.1053\/J.GASTRO.2016.04.003 (2016).","journal-title":"Gastroenterology"},{"key":"80082_CR15","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1128\/jvi.00253-11","volume":"85","author":"RA Fridell","year":"2011","unstructured":"Fridell, R. A. et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85, 7312\u20137320. https:\/\/doi.org\/10.1128\/jvi.00253-11 (2011).","journal-title":"J. Virol."},{"key":"80082_CR16","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1099\/VIR.0.034801-0","volume":"92","author":"D Qiu","year":"2011","unstructured":"Qiu, D. et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J. Gen. Virol. 92, 2502\u20132511. https:\/\/doi.org\/10.1099\/VIR.0.034801-0 (2011).","journal-title":"J. Gen. Virol."},{"key":"80082_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/NATURE08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao, M. et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465, 96\u2013100. https:\/\/doi.org\/10.1038\/NATURE08960 (2010).","journal-title":"Nature"},{"key":"80082_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/J.EJMECH.2019.02.016","volume":"167","author":"TK Yeh","year":"2019","unstructured":"Yeh, T. K. et al. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur. J. Med. Chem. 167, 245\u2013268. https:\/\/doi.org\/10.1016\/J.EJMECH.2019.02.016 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"80082_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/S40262-017-0624-3","volume":"57","author":"Y Gandhi","year":"2018","unstructured":"Gandhi, Y. et al. Daclatasvir: A review of preclinical and clinical pharmacokinetics. Clin. Pharmacokinet. 57, 911\u2013928. https:\/\/doi.org\/10.1007\/S40262-017-0624-3 (2018).","journal-title":"Clin. Pharmacokinet."},{"key":"80082_CR20","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1007\/s00044-011-9685-2","volume":"21","author":"SJ Kashyap","year":"2012","unstructured":"Kashyap, S. J. et al. Thiazoles: Having diverse biological activities. Med. Chem. Res. 21, 2123\u20132132. https:\/\/doi.org\/10.1007\/s00044-011-9685-2 (2012).","journal-title":"Med. Chem. Res."},{"issue":"1","key":"80082_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-41984-7","volume":"9","author":"S Alam","year":"2019","unstructured":"Alam, S. & Khan, F. 3D-QSAR, docking, ADME\/Tox studies on flavone analogs reveal anticancer activity through tankyrase inhibition. Sci. Rep. 9(1), 1\u201315. https:\/\/doi.org\/10.1038\/s41598-019-41984-7 (2019).","journal-title":"Sci. Rep."},{"key":"80082_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58485-x","author":"F Zare","year":"2024","unstructured":"Zare, F. et al. A combination of virtual screening, molecular dynamics simulation, MM\/PBSA, ADMET, and DFT calculations to identify a potential DPP4 inhibitor. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-024-58485-x (2024).","journal-title":"Sci. Rep."},{"key":"80082_CR23","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3390\/molecules27092729","volume":"27","author":"W Liman","year":"2022","unstructured":"Liman, W. et al. Monte carlo method and GA-MLR-based QSAR modeling of NS5A inhibitors against the hepatitis C virus. Molecules 27, 2729. https:\/\/doi.org\/10.3390\/molecules27092729 (2022).","journal-title":"Molecules"},{"key":"80082_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/MINF.201200069","volume":"32","author":"AP Toropova","year":"2013","unstructured":"Toropova, A. P. et al. CORAL: Monte carlo method as a tool for the prediction of the bioconcentration factor of industrial pollutants. Mol. Inform. 32, 145\u2013154. https:\/\/doi.org\/10.1002\/MINF.201200069 (2013).","journal-title":"Mol. Inform."},{"key":"80082_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3390\/ph16040608","volume":"16","author":"M Oubahmane","year":"2023","unstructured":"Oubahmane, M. et al. Design of potent inhibitors targeting the main protease of SARS-CoV-2 using QSAR modelling, molecular docking, and molecular dynamics simulations. Pharmaceuticals 16, 608. https:\/\/doi.org\/10.3390\/ph16040608 (2023).","journal-title":"Pharmaceuticals"},{"key":"80082_CR26","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1021\/ci800253u","volume":"48","author":"G Sch\u00fc\u00fcrmann","year":"2008","unstructured":"Sch\u00fc\u00fcrmann, G., Ebert, R. U., Chen, J., Wang, B. & K\u00fchne, R. External validation and prediction employing the predictive squared correlation coefficient\u2014test set activity mean vs training set activity mean. J. Chem. Inf. Model 48, 2140\u20132145. https:\/\/doi.org\/10.1021\/ci800253u (2008).","journal-title":"J. Chem. Inf. Model"},{"key":"80082_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1021\/acs.jcim.6b00088","volume":"56","author":"P Gramatica","year":"2016","unstructured":"Gramatica, P. & Sangion, A. A historical excursus on the statistical validation parameters for QSAR models: A clarification concerning metrics and terminology. J. Chem. Inf. Model 56, 1127\u20131131. https:\/\/doi.org\/10.1021\/acs.jcim.6b00088 (2016).","journal-title":"J. Chem. Inf. Model"},{"key":"80082_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/QSAR.200610151","volume":"26","author":"P Gramatica","year":"2007","unstructured":"Gramatica, P. Principles of QSAR models validation: Internal and external. QSAR Comb Sci 26, 694\u2013701. https:\/\/doi.org\/10.1002\/QSAR.200610151 (2007).","journal-title":"QSAR Comb Sci"},{"key":"80082_CR29","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1080\/14786419.2018.1493591","volume":"33","author":"AP Toropova","year":"2019","unstructured":"Toropova, A. P. & Toropov, A. A. The index of ideality of correlation: Improvement of models for toxicity to algae. Nat. Prod. Res. 33, 2200\u20132207. https:\/\/doi.org\/10.1080\/14786419.2018.1493591 (2019).","journal-title":"Nat. Prod. Res."},{"key":"80082_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/15376516.2018.1506851","volume":"29","author":"AA Toropov","year":"2019","unstructured":"Toropov, A. A. & Toropova, A. P. Use of the index of ideality of correlation to improve predictive potential for biochemical endpoints. Toxicol. Mech. Methods 29, 43\u201352. https:\/\/doi.org\/10.1080\/15376516.2018.1506851 (2019).","journal-title":"Toxicol. Mech. Methods"},{"key":"80082_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2024.105870","author":"N Ait Lahcen","year":"2024","unstructured":"Ait Lahcen, N. et al. Drug design of new anti-EBOV inhibitors: QSAR, homology modeling, molecular docking and molecular dynamics studies. Arab. J. Chem. https:\/\/doi.org\/10.1016\/j.arabjc.2024.105870 (2024).","journal-title":"Arab. J. Chem."},{"key":"80082_CR32","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/J.EJMECH.2011.01.018","volume":"46","author":"AA Toropov","year":"2011","unstructured":"Toropov, A. A. et al. CORAL: Building up the model for bioconcentration factor and defining it\u2019s applicability domain. Eur. J. Med. Chem. 46, 1400\u20131403. https:\/\/doi.org\/10.1016\/J.EJMECH.2011.01.018 (2011).","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"80082_CR33","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1038\/s41596-021-00597-z","volume":"16","author":"BJ Bender","year":"2021","unstructured":"Bender, B. J. et al. A practical guide to large-scale docking. Nat. Protoc. 16(10), 4799\u20134832. https:\/\/doi.org\/10.1038\/s41596-021-00597-z (2021).","journal-title":"Nat. Protoc."},{"key":"80082_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/AABC.S105289","volume":"9","author":"J de Ruyck","year":"2016","unstructured":"de Ruyck, J., Brysbaert, G., Blossey, R. & Lensink, M. F. Molecular docking as a popular tool in drug design, an in silico travel. Adv. Appl. Bioinform. Chem. 9, 1\u201311. https:\/\/doi.org\/10.2147\/AABC.S105289 (2016).","journal-title":"Adv. Appl. Bioinform. Chem."},{"key":"80082_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"X-Y Meng","year":"2011","unstructured":"Meng, X.-Y., Zhang, H.-X., Mezei, M. & Cui, M. Molecular Docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 7, 146. https:\/\/doi.org\/10.2174\/157340911795677602 (2011).","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"80082_CR36","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/ACS.JCIM.1C00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt, J., Santos-Martins, D., Tillack, A. F. & Forli, S. AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model 61, 3891\u20133898. https:\/\/doi.org\/10.1021\/ACS.JCIM.1C00203 (2021).","journal-title":"J. Chem. Inf. Model"},{"key":"80082_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/JCC.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/JCC.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"80082_CR38","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/JVI.02352-08","volume":"83","author":"RA Love","year":"2009","unstructured":"Love, R. A., Brodsky, O., Hickey, M. J., Wells, P. A. & Cronin, C. N. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 83, 4395\u20134403. https:\/\/doi.org\/10.1128\/JVI.02352-08 (2009).","journal-title":"J. Virol."},{"key":"80082_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1021\/ci400631n","volume":"55","author":"KH Barakat","year":"2015","unstructured":"Barakat, K. H. et al. A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J. Chem. Inf. Model 55, 362\u2013373. https:\/\/doi.org\/10.1021\/ci400631n (2015).","journal-title":"J. Chem. Inf. Model"},{"key":"80082_CR40","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.3390\/V6114227","volume":"6","author":"M Issur","year":"2014","unstructured":"Issur, M. & G\u00f6tte, M. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding. Viruses 6, 4227\u20134241. https:\/\/doi.org\/10.3390\/V6114227 (2014).","journal-title":"Viruses"},{"key":"80082_CR41","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785\u20132791. https:\/\/doi.org\/10.1002\/jcc.21256 (2009).","journal-title":"J. Comput. Chem."},{"key":"80082_CR42","unstructured":"BIOVIA Discovery Studio | Dassault Syst\u00e8mes. https:\/\/www.3ds.com\/products\/biovia\/discovery-studio. Accessed 4 January 2024."},{"key":"80082_CR43","unstructured":"PyMOL | pymol.org. https:\/\/pymol.org\/2\/. Accessed 4 January 2024."},{"key":"80082_CR44","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/ACS.JCTC.5B00255","volume":"11","author":"JA Maier","year":"2015","unstructured":"Maier, J. A. et al. ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 11, 3696\u20133713. https:\/\/doi.org\/10.1021\/ACS.JCTC.5B00255 (2015).","journal-title":"J. Chem. Theory Comput."},{"key":"80082_CR45","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/ct1002626","volume":"6","author":"MB Peters","year":"2010","unstructured":"Peters, M. B. et al. Structural survey of zinc-containing proteins and development of the zinc AMBER force field (ZAFF). J. Chem. Theory Comput. 6, 2935\u20132947. https:\/\/doi.org\/10.1021\/ct1002626 (2010).","journal-title":"J. Chem. Theory Comput."},{"key":"80082_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/WCMS.1121","volume":"3","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer, R., Case, D. A. & Walker, R. C. An overview of the Amber biomolecular simulation package. Wiley Interdiscip Rev. Comput. Mol. Sci. 3, 198\u2013210. https:\/\/doi.org\/10.1002\/WCMS.1121 (2013).","journal-title":"Wiley Interdiscip Rev. Comput. Mol. Sci."},{"key":"80082_CR47","unstructured":"ParmEd\u2014ParmEd documentation. https:\/\/parmed.github.io\/ParmEd\/html\/index.html. Accessed 8 April 2024."},{"key":"80082_CR48","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/JCC.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: Fast, flexible, and free. J Comput Chem 26, 1701\u20131718. https:\/\/doi.org\/10.1002\/JCC.20291 (2005).","journal-title":"J Comput Chem"},{"key":"80082_CR49","unstructured":"Grace Home. https:\/\/plasma-gate.weizmann.ac.il\/Grace\/. Accessed 10 April 2024."},{"key":"80082_CR50","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco, M. S., Vald\u00e9s-Tresanco, M. E., Valiente, P. A. & Moreno, E. Gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. J. Chem. Theory Comput. 17, 6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645 (2021).","journal-title":"J. Chem. Theory Comput."},{"key":"80082_CR51","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-1-4939-7756-7_14","volume":"1762","author":"DEV Pires","year":"2018","unstructured":"Pires, D. E. V., Kaminskas, L. M. & Ascher, D. B. Prediction and optimization of pharmacokinetic and toxicity properties of the ligand. Methods Mol. Biol. 1762, 271\u2013284. https:\/\/doi.org\/10.1007\/978-1-4939-7756-7_14 (2018).","journal-title":"Methods Mol. Biol."},{"key":"80082_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/CMDC.202100542","author":"SQ Pantale\u00e3o","year":"2022","unstructured":"Pantale\u00e3o, S. Q., Fernandes, P. O., Gon\u00e7alves, J. E., Maltarollo, V. G. & Honorio, K. M. Recent advances in the prediction of pharmacokinetics properties in drug design studies: A review. Chem. Med. Chem. https:\/\/doi.org\/10.1002\/CMDC.202100542 (2022).","journal-title":"Chem. Med. Chem."},{"key":"80082_CR53","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/ACS.JMEDCHEM.5B00104","volume":"58","author":"DEV Pires","year":"2015","unstructured":"Pires, D. E. V., Blundell, T. L. & Ascher, D. B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58, 4066\u20134072. https:\/\/doi.org\/10.1021\/ACS.JMEDCHEM.5B00104 (2015).","journal-title":"J. Med. Chem."},{"key":"80082_CR54","unstructured":"Molecular Properties Prediction\u2014Osiris Property Explorer. https:\/\/www.organic-chemistry.org\/prog\/peo\/. Accessed 4 January 2024."},{"key":"80082_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1093-3263(01)00123-1","volume":"20","author":"A Golbraikh","year":"2002","unstructured":"Golbraikh, A. & Tropsha, A. Beware of q2!. J. Mol. Graph Model 20, 269\u2013276. https:\/\/doi.org\/10.1016\/S1093-3263(01)00123-1 (2002).","journal-title":"J. Mol. Graph Model"},{"key":"80082_CR56","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/J.CHEMOLAB.2011.03.011","volume":"107","author":"PK Ojha","year":"2011","unstructured":"Ojha, P. K., Mitra, I., Das, R. N. & Roy, K. Further exploring rm2 metrics for validation of QSPR models. Chemom. Intell. Lab. Syst. 107, 194\u2013205. https:\/\/doi.org\/10.1016\/J.CHEMOLAB.2011.03.011 (2011).","journal-title":"Chemom. Intell. Lab. Syst."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80082-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80082-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T10:04:44Z","timestamp":1735639484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80082-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80082"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80082-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31655"}}